Carolyn DaSilva

Odanacatib, a cathepsin-K inhibitor for osteoporosis: A two-year study in postmenopausal women with low bone density

Henry G. Bone, Michael R. McClung, Christian Roux et al. · Journal of Bone and Mineral Research · 2009 · 331 citations

Medicine, Pharmacotherapy, Bone Metabolism +16

Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect

John A. Eisman, Henry G. Bone, David Hosking et al. · Journal of Bone and Mineral Research · 2010 · 246 citations · Full text

Medicine, Pharmacotherapy, Bone Grafting +16

Inhibition of T Cell Activation by Pharmacologic Disruption of the MEK1/ERK MAP Kinase or Calcineurin Signaling Pathways Results in Differential Modulation of Cytokine Production

Francis J. Dumont, Mary Jo Staruch, Paul Fischer et al. · The Journal of Immunology · 1998 · 187 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study

Michael R. McClung, Michelle L. O’Donoghue, Socrates E. Papapoulos et al. · The Lancet Diabetes & Endocrinology · 2019 · 169 citations

Pharmacy, Pharmacotherapy, Bone Metabolism +10

Odanacatib in the treatment of postmenopausal women with low bone mineral density: Five years of continued therapy in a phase 2 study

Bente Langdahl, Neil Binkley, Henry G. Bone et al. · Journal of Bone and Mineral Research · 2012 · 160 citations

Medicine, Pharmacotherapy, Bone Metabolism +16